iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) and Fate Therapeutics (NASDAQ:FATE – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Profitability
This table compares iTeos Therapeutics and Fate Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
iTeos Therapeutics | N/A | -20.11% | -17.50% |
Fate Therapeutics | -1,325.43% | -45.88% | -33.95% |
Earnings & Valuation
This table compares iTeos Therapeutics and Fate Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
iTeos Therapeutics | $12.60 million | 21.45 | -$112.64 million | ($3.15) | -2.35 |
Fate Therapeutics | $63.53 million | 2.55 | -$160.93 million | ($1.65) | -0.86 |
Volatility and Risk
iTeos Therapeutics has a beta of 1.38, meaning that its stock price is 38% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.
Analyst Ratings
This is a summary of recent recommendations for iTeos Therapeutics and Fate Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
iTeos Therapeutics | 0 | 0 | 4 | 0 | 3.00 |
Fate Therapeutics | 0 | 7 | 3 | 0 | 2.30 |
iTeos Therapeutics currently has a consensus target price of $22.25, suggesting a potential upside of 200.68%. Fate Therapeutics has a consensus target price of $6.75, suggesting a potential upside of 375.35%. Given Fate Therapeutics’ higher probable upside, analysts plainly believe Fate Therapeutics is more favorable than iTeos Therapeutics.
Institutional and Insider Ownership
97.2% of iTeos Therapeutics shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 12.5% of iTeos Therapeutics shares are held by insiders. Comparatively, 5.0% of Fate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
iTeos Therapeutics beats Fate Therapeutics on 8 of the 14 factors compared between the two stocks.
About iTeos Therapeutics
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
About Fate Therapeutics
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.